<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25248287</article-id>
      <article-id pub-id-type="pmc">4180964</article-id>
      <article-id pub-id-type="publisher-id">3833</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2334-14-514</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Decolonization of gastrointestinal carriage of vancomycin-resistant <italic>Enterococcus faecium</italic>: case series and review of literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>Vincent CC</given-names>
          </name>
          <address>
            <email>vcccheng@hkucc.hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Jonathan HK</given-names>
          </name>
          <address>
            <email>jonchk@hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tai</surname>
            <given-names>Josepha WM</given-names>
          </name>
          <address>
            <email>taijosepha@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wong</surname>
            <given-names>Sally CY</given-names>
          </name>
          <address>
            <email>scywong@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Poon</surname>
            <given-names>Rosana WS</given-names>
          </name>
          <address>
            <email>rosanapws@yahoo.com.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hung</surname>
            <given-names>Ivan FN</given-names>
          </name>
          <address>
            <email>ivanfn@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>To</surname>
            <given-names>Kelvin KW</given-names>
          </name>
          <address>
            <email>kelvinto@hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chan</surname>
            <given-names>Jasper FW</given-names>
          </name>
          <address>
            <email>jaspchan@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ho</surname>
            <given-names>Pak-Leung</given-names>
          </name>
          <address>
            <email>plho@hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lo</surname>
            <given-names>Chung-Mau</given-names>
          </name>
          <address>
            <email>cmlo@hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yuen</surname>
            <given-names>Kwok-Yung</given-names>
          </name>
          <address>
            <email>kyyuen@hkucc.hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China </aff>
        <aff id="Aff2"><label/>Infection Control Team, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China </aff>
        <aff id="Aff3"><label/>Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China </aff>
        <aff id="Aff4"><label/>Department of Surgery, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <elocation-id>514</elocation-id>
      <history>
        <date date-type="received">
          <day>6</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Cheng et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Prolonged asymptomatic carriage of vancomycin-resistant enterococci (VRE) in the gastrointestinal tract and the lack of effective decolonization regimen perpetuate the endemicity of VRE in the healthcare settings.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report a regimen for decolonization of gastrointestinal carriage of VRE by a combination of environmental disinfection, patient isolation, bowel preparation to wash-out the fecal bacterial population using polyethylene glycol, a five-day course of oral absorbable linezolid and non-absorbable daptomycin to suppress any remaining VRE, and subsequent oral <italic>Lactobacillus rhamnosus</italic> GG to maintain the colonization resistance in four patients, including two patients with end-stage liver cirrhosis, one patient with complication post liver transplant, and one patient with complicated infective endocarditis. All patients had clearance of VRE immediately after decolonization, and 3 of them remained VRE-free for 23 to 137 days of hospitalization, despite subsequent use of intravenous broad-spectrum antibiotics without anti-VRE activity.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This strategy should be further studied in settings of low VRE endemicity with limited isolation facilities.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1186/1471-2334-14-514) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Vancomycin-resistant enterococci</kwd>
        <kwd>Decolonization</kwd>
        <kwd>Bowel preparation</kwd>
        <kwd>Polyethylene glycol</kwd>
        <kwd>Linezolid</kwd>
        <kwd>Daptomycin</kwd>
        <kwd><italic>Lactobacillus rhamnosus</italic> GG</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Vancomycin-resistant enterococci (VRE) has been endemic in many parts of the word. Prolonged asymptomatic carriage of VRE in the gastrointestinal tract and the lack of effective decolonization regimen perpetuate the endemicity of VRE in the healthcare settings [<xref ref-type="bibr" rid="CR1">1</xref>]. In Hong Kong, an increasing number of sporadic cases of VRE are observed, with a prevalence of 0.32% of admission episodes by active surveillance culture [<xref ref-type="bibr" rid="CR2">2</xref>]. We adopted a proactive infection measures by the implementation of active surveillance culture, extensive contact tracing, isolation of VRE-positive patients and environmental disinfection to control nosocomial transmission of VRE [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. However, the limited availability of single rooms fails to match with the increasing number of patients colonized with VRE in recent years. Therefore, an effective regimen for VRE decolonization is necessary in resource-limited areas like Hong Kong. Here, we report a protocol of VRE decolonization in four patients, including two patients with end-stage liver cirrhosis awaiting liver transplantation, one patient with a complicated post-liver transplant recovery, and one patient with complicated infective endocarditis. Decolonization of VRE is crucial in liver transplant candidates as VRE colonization is associated with an increased risk of infection and death among liver transplant recipients [<xref ref-type="bibr" rid="CR5">5</xref>]. In contrast to the previous attempt of VRE decolonization using only antimicrobial agents or probiotics, we include the use of polyethylene glycol for bowel preparation to wash-out the fecal bacterial population prior to the administration of oral linezolid and daptomycin. <italic>Lactobacillus rhamnosus</italic> GG is then given to maintain the colonization resistance after antimicrobial decolonization. Our aim of VRE decolonization was to reduce the risk of subsequent invasive VRE infection among the high-risk patients, and to limit the risk of nosocomial transmission of VRE in our locality.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Decolonization of gastrointestinal carriage of VRE</title>
        <p>Case 1: A 59-year-old man was referred to the Liver Transplant Unit of Queen Mary Hospital, a university-affiliated hospital with 1,600 bed, for consideration of cadaveric liver transplantation due to chronic hepatitis B-related end-stage cirrhosis on 14 September 2013. Queen Mary Hospital is the only liver transplant center in Hong Kong, with approximately 80 patients undergoing liver transplantation per year. Upon admission, rectal swab with visible stool content was collected for the detection of multidrug-resistant organisms including VRE in accordance to the hospital infection control policy. Briefly, patients with history of hospitalization or receiving surgical operation outside Hong Kong within the past 12&#xA0;months before admission or patients with history of admissions to other local hospitals within the past 3&#xA0;months were included in the active surveillance [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The patient was confirmed to be positive for vancomycin-resistant <italic>Enterococcus faecium</italic> which was resistant to ampicillin, chloramphenicol, nitrofurantoin, levofloxacin, minocycline, rifampicin, tetracycline, fosfomycin, high-level gentamicin, and high-level streptomycin. The minimal inhibitory concentration (MIC) of vancomycin was &gt;256&#xA0;&#x3BC;g/ml. <italic>VanA</italic> gene was detected by polymerase chain reaction (PCR). The MIC of linezolid and daptomycin was 1.5&#xA0;&#x3BC;g/ml and 3.0&#xA0;&#x3BC;g/ml respectively, while the MIC breakpoint of linezolid and daptomycin was&#x2009;&#x2264;&#x2009;2&#xA0;&#x3BC;g/ml and&#x2009;&#x2264;&#x2009;4&#xA0;&#x3BC;g/ml for enterococcus species respectively with reference to Clinical and Laboratory Standards Institute. Multilocus sequence typing (MLST) demonstrated that the strain was ST761 (profile 70-1-1-1-12-1-1), which is a member of the pandemic clonal complex 17 lineage. The patient was isolated in a single room with strict contact precautions since day 2 of hospitalization. Healthcare workers wore gloves and gowns during patient care practice. Alcohol-based hand rub was provided in the isolation room for hand hygiene. Dedicated medical items such as stethoscope, thermometer, and blood pressure cuff were available and solely used on this patient. Decolonization of VRE was performed between day 11 and 15 of hospitalization according to our protocol (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). The bacterial load of VRE in rectal swabs with visible stool content was monitored daily. The VRE counts decreased from &gt;2&#xD7;10<sup>5</sup> colony forming units per gram (cfu/g) of stool (baseline on day 11) to 3.4&#xD7;10<sup>4</sup> cfu/g of stool on day 12 and undetectable (&lt;200&#xA0;cfu/g) on day 13. Despite the administration of broad-spectrum antibiotics after successful decolonization, the serial rectal swabs remained negative for VRE in vancomycin and clindamycin containing enterococcal enrichment broth culture (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). ABO blood group matched-cadaveric liver graft became available on day 30 of hospitalization and transplantation was performed under coverage with intravenous linezolid 600&#xA0;mg 30&#xA0;minutes before surgical incision, and one dose postoperatively. The operation lasted for 11&#xA0;hours without immediate complications. Patient was managed in the adult intensive care unit during the postoperative period and transferred to the liver transplant ward on day 32 of hospitalization (post-operative day 2). Serial rectal swabs were collected on day 1, 3, 4, 5, 7, 10, 12, 14, and 17 after liver transplantation, thereafter twice weekly until day 66, and weekly until day 107 after liver transplantation (day 137 of hospitalization) (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). No growth of VRE was detected in broth enrichment culture.Case 2: A 56-year-old man had living-donor liver transplantation for early stage of moderately differentiated hepatocellular carcinoma on 31 July 2012. He developed recurrent ascites as a result of portal vein and hepatic vein stenosis 6&#xA0;months post-transplant requiring multiple episodes of hospitalization. On 26 February 2014, he was detected to have gastrointestinal colonization of VRE and was subjected to VRE decolonization after 13&#xA0;days of hospitalization (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). However, patient had poor tolerance to oral ingestion of polyethylene glycol for bowel preparation due to refractory ascites. Since the procedure of decolonization was started, it was continued despite insufficient bowel preparation. Patient had transient suppression of VRE between day 14 and 19 and VRE relapsed on day 27 of hospitalization. The decolonization regimen was not successful in this case with inadequate bowel preparation.Case 3: A 44-year-old man was transferred from a regional hospital to the Liver Transplant Unit of Queen Mary Hospital for consideration of cadaveric liver transplantation due to hepatitis B-related hepatic failure on 15 March 2014. He was found to have gastrointestinal carriage of VRE upon admission screening. While waiting for a potential liver graft, VRE decolonization was initiated on day 5 of hospitalization. He remained VRE negative on serial monitoring till day 62 of hospitalization despite intermittent use of antibiotics (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).Case 4: A 71-year-old-lady was transferred from a regional hospital to the Cardiothoracic Surgical Unit, Queen Mary Hospital, for consideration of surgical intervention for viridans streptococci-related infective endocarditis complicated with cardiac failure. She had history of chronic rheumatic heart disease with mitral stenosis, mitral regurgitation, aortic regurgitation, and tricuspid regurgitation. She was noted to have gastrointestinal carriage of VRE upon admission screening, and was put on VRE decolonization as per protocol on day 10 of hospitalization. Serial rectal swabs culture remained VRE negative (broth enrichment culture) till day 23 of hospitalization (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). However, patient developed respiratory distress, metabolic acidosis, hypotension, oliguric renal impairment, and radiological appearance of dilated bowel loops suggestive of mesenteric ischemia on day 25. Urgent exploratory laparotomy revealed the presence of 300&#xA0;ml foul-smelling, blood-stained peritoneal fluid with gangrenous change of bowel from duodenojejunal flexure to mid-sigmoid colon. Despite empirical use of meropenem and daptomycin, inotropic and ventilator support, patient succumbed on day 26 of hospitalization. No VRE could be detected in all her clinical specimens or serial rectal swabs after decolonization.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Protocol of vancomycin-resistant enterococci decolonization</bold>*</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>1.</td><td>Patient was managed in isolation room A and subjected to bowel preparation according to the protocol commonly used prior to colonoscopy examination: (i) ingestion of 2 liters of polyethylene glycol (Klean prep) over 6&#xA0;hours to wash out the bowel content; (ii) taking fluid diet including rice water, clear soup, and fruit juice on the first day of decolonization.</td></tr><tr><td>2.</td><td>When the defecated bowel content became clear fluid, patient was transferred from isolation room A to B, which had been terminally disinfected with sodium hypochlorite 1,000&#xA0;ppm.</td></tr><tr><td>3.</td><td>After transferal to isolation room B, a five-day course of medication with activity against VRE was given, including oral linezolid 600&#xA0;mg every 12 hourly, orally-taken intravenous preparation of daptomycin 8&#xA0;mg per kg daily.</td></tr><tr><td>4.</td><td>At the same time, the patient was cleansed with 4% chlorhexidine bath and shampoo, and oral chlorhexidine gargle for 5&#xA0;days. Where possible, avoid use of other antibiotics treatment during the decolonization period.</td></tr><tr><td>5.</td><td>At the time of bathing, the patient&#x2019;s clothes, underwear, and bed linens were replaced and sent for hot laundry daily. All personal belongings were disinfected to prevent re-colonization. The isolation room was thoroughly cleaned and disinfected by sodium hypochlorite 1,000&#xA0;ppm twice daily.</td></tr><tr><td>6.</td><td>After completion of 5-day decolonization regimen, <italic>Lactobacillus rhamnosus</italic> GG 80&#xA0;mg was given daily to replace the gut flora.</td></tr><tr><td>7.</td><td>All foods and drinks throughout the decolonization procedure must be boiled. All visitors and healthcare workers must comply with hand hygiene with alcohol based hand rub.</td></tr></tbody></table><table-wrap-foot><p>Note. VRE, vancomycin-resistant enterococci; *The decolonization protocol was designed and coordinated by the infection control team for all patients in Queen Mary Hospital. Infection control nurses closely monitored and audited the compliance of the procedures required for decolonization.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Serial quantitative culture of gastrointestinal carriage of vancomycin</bold>-<bold>resistant</bold>
<bold><italic>Enterococcus faecium</italic></bold>
<bold>and concomitant use of antimicrobial agents in case 1.</bold> Note. Intravenous meropenem 500&#xA0;mg every 8 hourly was given between day 16 and 31 for recurrent isolation of extended-spectrum &#x3B2;-lactamase-producing <italic>Klebsiella species</italic> in sputum; intravenous meropenem 500&#xA0;mg every 8 hourly was given again between day 41 and 49 for low grade fever without microbiological documentation of infection; oral levofloxacin 750&#xA0;mg daily was given between day 71 and 78 for urine isolation of extended-spectrum &#x3B2;-lactamase-producing <italic>Klebsiella species</italic>; oral cotrimoxazole 480&#xA0;mg twice daily was given after liver transplantation as pre-emptive prophylactic agent. The dotted horizontal line denoted the detection limit of VRE in fecal samples by broth enrichment&#x2009;~&#x2009;200&#xA0;cfu/g (2.3 log<sub>10</sub> cfu/g).</p></caption><graphic xlink:href="12879_2014_Article_3833_Fig1_HTML" id="d30e532"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Serial quantitative culture of gastrointestinal carriage of vancomycin</bold>-<bold>resistant</bold>
<bold><italic>Enterococcus faecium</italic></bold>
<bold>and concomitant use of antimicrobial agents in case 2.</bold> Note. Intravenous piperacillin-tazobactam 4.5 gm iv q12h, daptomycin 250&#xA0;mg iv q12h, and metronidazole 500&#xA0;mg iv q8h were given from day 3 for empirical treatment of spontaneous bacterial peritonitis, while intravenous piperacillin-tazobactam 4.5 gm iv q12h, and daptomycin 250&#xA0;mg iv q12h were given between day 45 and 56 for clinical diagnosis of another episode of spontaneous bacterial peritonitis. The dotted horizontal line denoted the detection limit of VRE in fecal samples by broth enrichment&#x2009;~&#x2009;200&#xA0;cfu/g (2.3 log10 cfu/g).</p></caption><graphic xlink:href="12879_2014_Article_3833_Fig2_HTML" id="d30e553"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Serial quantitative culture of gastrointestinal carriage of vancomycin</bold>-<bold>resistant</bold>
<bold><italic>Enterococcus faecium</italic></bold>
<bold>and concomitant use of antimicrobial agents in case 3.</bold> Note. Intravenous cefotaxime 1 gm iv q8h was given from the referral hospital and stopped on day 1 of hospitalization. Amoxicillin-clavulanate was given on day 20 and stepped up to piperacillin-tazobactam on day 24 of hospitalization for nosocomial onset of fever of unknown source. The dotted horizontal line denoted the detection limit of VRE in fecal samples by broth enrichment&#x2009;~&#x2009;200&#xA0;cfu/g (2.3 log<sub>10</sub> cfu/g).</p></caption><graphic xlink:href="12879_2014_Article_3833_Fig3_HTML" id="d30e577"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Serial quantitative culture of gastrointestinal carriage of vancomycin</bold>-<bold>resistant</bold>
<bold><italic>Enterococcus faecium</italic></bold>
<bold>and concomitant use of antimicrobial agents in case 4.</bold> Note. Intravenous ampicillin 2 gm iv q8h, and gentamicin 40 mg iv q8h were given from the referral hospital for treatment of infective endocarditis due to viridans streptococci. Antibiotic was changed to benzyl penicillin 3 MU iv q4h on day 7 upon clinical consultation to microbiologist, and stopped on day 17 of hospitalization after completion of treatment. Meropenem 500 mg iv q12h and one dose of daptomycin 350 mg iv was given on day 25 for systemic sepsis complicating mesenteric ischemia and bowel gangrene. Patient succumbed on day 26 of hospitalization despite maximal supportive therapy. The dotted horizontal line denoted the detection limit of VRE in fecal samples by broth enrichment ~ 200 cfu/g (2.3 log<sub>10</sub> cfu/g).</p></caption><graphic xlink:href="12879_2014_Article_3833_Fig4_HTML" id="d30e601"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Microbiological analysis</title>
        <p>For VRE screening, stool or rectal swabs with visible fecal components were inoculated onto chromogenic agar (chromID VRE, bioMerieux, France) and incubated aerobically at 35&#xB0;C for 48&#xA0;hours for identification by Vitek 2 automated identification system (bioMerieux, France) as previously described [<xref ref-type="bibr" rid="CR4">4</xref>]. The Kirby-Bauer disk diffusion method and E-test (AB Biodisk, Solna, Sweden) were used to determine the antimicrobial susceptibility of the enterococci. Isolates with potential vancomycin resistance were proceeded to <italic>vanA</italic> gene PCR and MLST as previously described [<xref ref-type="bibr" rid="CR4">4</xref>]. For VRE bacterial load quantitation, around 1&#xA0;g of fecal sample was suspended into 2&#xA0;ml normal saline and serially diluted suspensions were plated onto chromogenic agar. In addition, broth enrichment was performed by inoculating another 10&#xA0;&#x3BC;l aliquot of the fecal suspension into the vancomycin containing brain-heart-infusion broth. The broth was incubated at 37&#xB0;C overnight and further subcultured onto chromogenic agar in 35&#xB0;C aerobic incubation for 48&#xA0;hours. The lower detection limit of this method is 200&#xA0;cfu/g.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Discussion</title>
      <p>Decolonization of VRE poses a great challenge for clinical microbiologists and infection control professionals. It is difficult to suppress the fecal burden of enterococci, ranging from 1&#x2013;10 million cfu/g of stool, within the gastrointestinal tract by sole use of antimicrobial agents that are only bacteriostatic. We aim to overcome the problem of significant enterococci burden by mechanical removal of fecal load before the administration of high concentration of topical antimicrobial agents. Therefore, in addition to systemic and topical antibiotics, we adopt a protocol for bowel wash-out commonly used prior to colonoscopy to remove the majority of the fecal bacterial burden, and combined it with adjunctive infection control measures and probiotic. To our knowledge, the use of polyethylene glycol for bowel preparation in the aim to eliminate fecal bacterial population has not been attempted in previous eradication protocols for VRE or other multiple drug resistant bacteria. We have successfully eradicated VRE carriage in a high-risk patient with end-stage cirrhosis before cadaveric liver transplantation. This patient was chosen as the first case in our pilot study because decolonization of VRE is crucial in liver transplant candidates. In one study, it was found that liver transplant candidates and recipients with VRE colonization had an increased risk of VRE infection (adjusted odd ratio 3.61, 95% CI 2.01-6.47) and of death (adjusted odd ratio 2.12, 95% CI 1.27-3.54) compared with non-colonized patients [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>In the literature, antimicrobial agents with high luminal concentration had been used to decolonize gastrointestinal carriage of VRE in 142 patients (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Bacitracin-containing regimens given orally or via gastrostomy tube for 10&#xA0;days to 29&#xA0;days were most common, and was used in 76 (54%) of 142 patients [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. The results were rather variable, while the overall observed rate of VRE clearance was found to be 43% to 100% in patients treated with bacitracin-containing regimens [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], long term follow up showed that VRE free was only observed in 33% to 53% at 3&#xA0;weeks post-treatment [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. In one study using a combination of oral bacitracin and doxycycline as VRE eradication regimen, although quantitation of VRE in stool showed an initial 3-log reduction of VRE count per gram of stool during the 2-week therapy, the VRE count in stool increased to pretreatment levels of 7.8 and 7.4 log<sub>10</sub>/g at 2&#x2013;4 and 5&#x2013;7 weeks post-treatment respectively [<xref ref-type="bibr" rid="CR9">9</xref>]. In another randomized placebo controlled study to assess the use of 10-day course of zinc bacitracin capsules in enteric eradication of VRE, only 2 (33%) of 6 patients in each group were VRE negative after 3&#xA0;weeks suggesting that there was no difference in eradication rate of VRE in the zinc bacitracin and the control group [<xref ref-type="bibr" rid="CR10">10</xref>]. In a later study, combination of oral bacitracin and gentamicin was evaluated. After 3&#xA0;months of follow up, only 5 (18%) of 28 patients had no VRE isolated from stool cultures. Antimicrobial side effects were a major concern. Of the 45 patients originally enrolled on the treatment arm, 17 (38%) could not tolerate bacitracin and gentamicin because of nausea, vomiting, and diarrhea [<xref ref-type="bibr" rid="CR12">12</xref>]. Ramoplanin, an orally administered lipoglycodepsipeptide antibiotic that is not absorbed systemically, has in vitro activity against vancomycin-resistant <italic>E. faecium</italic> and <italic>E. faecalis</italic>, and has been shown to suppress gastrointestinal colonization of VRE in up to 90% of patients during the course of ramoplanin in a phase II, double-blinded, randomized, multicenter, placebo-controlled study. However, recurrence of VRE colonization was observed in most patients 14&#xA0;days after treatment [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Short courses of novobiocin in combination with tetracycline or doxycycline were also ineffective in eradicating gastrointestinal carriage of VRE [<xref ref-type="bibr" rid="CR15">15</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Summary of gastrointestinal decolonization of vancomycin</bold>-<bold>resistant Enterococcus by antimicrobial therapy</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ref</th><th>Country/year of publication/study setting</th><th>Decolonization regimens/study end point(if mentioned)</th><th>Results at study end point</th><th>Microbiology culture methods/presence of broth enrichment or not</th></tr></thead><tbody><tr><td>[<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>US/1994/observational study</td><td>Oral vancomycin 125&#xA0;mg q6h for 10&#xA0;days<sup>a</sup>/follow up for 15&#xA0;days post treatment</td><td>VRE negative in 8 (42%) of 19 patients</td><td>Campylobacter agar containing 10&#xA0;&#x3BC;g/ml of vancomycin (B-D Microbiology Systems, Cockeysville, MD, USA)/no broth enrichment</td></tr><tr><td>[<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>US/1994/observational study</td><td>Oral bacitracin 25,000 U (500&#xA0;mg) q6h for 10&#xA0;days/follow up for 15&#xA0;days post treatment</td><td>VRE negative in 8 (100%) of 8 patients</td><td>Campylobacter agar containing 10&#xA0;&#x3BC;g/ml of vancomycin (B-D Microbiology Systems, Cockeysville, MD, USA)/no broth enrichment</td></tr><tr><td>[<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>US/1995/observational study</td><td>Oral novobiocin (500&#xA0;mg q6h plus oral tetracycline 500&#xA0;mg q6h (five patients) or intravenous doxycycline 100&#xA0;mg q12h (one patient) for a median of 3.5&#xA0;days (range, 1 to 6&#xA0;days)</td><td>VRE negative in only one patient while receiving decolonization therapy</td><td>Not mentioned</td></tr><tr><td>[<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>US/1995/observational study</td><td>Bacitracin 25,000 U (diluted in 5&#xA0;mL of 0.9% normal saline) given orally or by gastrostomy tube twice a day for 10&#xA0;days/follow up for 3&#xA0;weeks post treatment</td><td>VRE negative in 5 (63%) of 8 patients</td><td>Not mentioned</td></tr><tr><td>[<xref ref-type="bibr" rid="CR9">9</xref>]</td><td>Canada/1999/prospective observational cohort study in a tertiary care institution</td><td>Oral doses of bacitracin solution (75,000 U/15 mL) four times daily and doxycycline 100&#xA0;mg once daily for 14&#xA0;days/follow up for 4&#xA0;months</td><td>VRE negative in 15 (100%) of the antibiotic treated vs 8 (33.3%) of the untreated patients (P &lt;0 .001) at the end of treatment; but VRE positive in 9 (60%) of 15 and 15 (62.5%) of 24 in the treated and untreated cohort (p&#x2009;=&#x2009;0.86) following up for a mean of 127 and 130&#xA0;days respectively <sup>b</sup>
</td><td>M-enterococcal agar with vancomycin (6&#xA0;mg/mL)/no broth enrichment</td></tr><tr><td>[<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>US/2001/randomized, controlled study</td><td>Oral zinc bacitracin (50,000 U) q6h for 10&#xA0;days vs placebo/follow up for 3&#xA0;weeks post treatment</td><td>VRE negative in 2 (33%) of 6 patients in each group after 3&#xA0;weeks post treatment</td><td>Bile esculin agar plates supplemented with 6&#xA0;mg/mL of vancomycin/no broth enrichment</td></tr><tr><td>[<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>US/2001/phase II, double-blinded, randomized, multicenter, placebo-controlled study</td><td>Oral ramoplanin: 2 daily doses of 100&#xA0;mg or 400&#xA0;mg or placebo for 7&#xA0;days/follow up on day 0, 7, and 14 post treatment</td><td>Day 0: VRE negative in 17 (81%) of 21 and 18 (90%) of 20 patients in the 100-mg and 400-mg ramoplanin groups; Day 7: VRE negative in 6 (29%) of 21 and 7 (41%) of 17 in the 100-mg and 400-mg ramoplanin groups; Day 14: VRE negative in 4 (21%) of 19 and 5 (29%) of 17 patients in the 100-mg and 400-mg ramoplanin groups<sup>c</sup>
</td><td>Bile-esculin azide broth that contained 6&#xA0;mg/mL of vancomycin (Hardy Diagnostics)/broth enrichment</td></tr><tr><td>[<xref ref-type="bibr" rid="CR12">12</xref>]</td><td>US/2002/observational study</td><td>Oral bacitracin (25,000 U three times daily) and oral gentamicin (80&#xA0;mg three times daily) for a mean duration of 16&#xA0;days (median, 14&#xA0;days; range, 7 to 29&#xA0;days)/follow up for 3&#xA0;months post treatment</td><td>VRE negative in 5 (17.8%) of 28 patients</td><td>Not mentioned</td></tr><tr><td>[<xref ref-type="bibr" rid="CR11">11</xref>]</td><td>France/2010/observational study in a geriatric rehabilitation care facility</td><td>Oral bacitracin 30,000 U three times daily for 15&#xA0;days/follow up for 6&#xA0;months</td><td>VRE negative in 3 (43%) of 7 patients at the end of therapy and at 6&#xA0;months</td><td>Not mentioned</td></tr><tr><td>[<xref ref-type="bibr" rid="CR11">11</xref>]</td><td>France/2010/observational study in a geriatric rehabilitation care facility</td><td>Bacitracin 30,000 U three times daily plus streptomycin 1&#xA0;g once daily orally for 15&#xA0;days/follow up for 6&#xA0;months</td><td>VRE negative in 3 (75%) of 4 patients at the end of therapy and at 6&#xA0;months</td><td>Not mentioned</td></tr></tbody></table><table-wrap-foot><p>Note. U, units; VRE, vancomycin-resistant enterococci; <sup>a</sup>high intraluminal concentrations attained with oral vancomycin administration greatly exceed the MICs of VRE; <sup>b</sup>Quantitative VRE stool cultures in the treated cohort revealed an initial 3.1 log<sub>10</sub>/g decrease, but there was an increase to pretreatment levels of 7.8 and 7.4 log<sub>10</sub>/g at 2&#x2013;4 and 5&#x2013;7 weeks post-treatment respectively; <sup>c</sup>For placebo group, VRE negative in none of 20 patients in day 0, 2 (10%) of 20 patients in day 7, and 5 (25%) of 20 patients in day 14 post treatment.</p></table-wrap-foot></table-wrap></p>
      <p>With reference to the suboptimal VRE eradication outcomes in the literature when antimicrobial treatment was used alone without fecal wash-out, we attempted to reduce the microbial burden of the gastrointestinal tract by performing bowel wash-out prior to antimicrobial treatment. In addition, we used a new combination of a 5-day course of oral linezolid with systemic effect and oral non-absorbable daptomycin with topical effect to maximize the anti-VRE activity in the gastrointestinal tract. Daptomycin oral therapy had previously been given with minimal systemic absorption [<xref ref-type="bibr" rid="CR16">16</xref>]. Oral absorbable linezolid may help to decrease VRE counts in biliary or urinary system, but even systemic antibiotics may not work if patients have stone or parasitic nidus in the biliary or urinary tract associated with biofilm formation which can be colonized by VRE. Thus organ imaging to exclude these kinds of foci would be important before instituting the decolonization. This regimen successfully reduced the quantitative bacterial count of VRE from 10<sup>4</sup> - 10<sup>5</sup>&#xA0;cfu/g of stool to undetectable level within 3&#xA0;days of decolonization therapy in at least 3 patients (case 1, case 3, and case 4). However, our regimen failed in one patient (case 2) who could not tolerate oral ingestion of polyethylene glycol for bowel preparation due to refractory ascites. We believe that complete fecal wash-out is the key component of our VRE decolonization regimen.</p>
      <p>Adjunctive infection control measures are essential to prevent re-acquisition of VRE from patients&#x2019; skin and hospital environment during the process of decolonization. Preparation of 4% chlorhexidine gluconate bath and shampoo was used to reduce the cutaneous colonization of VRE as previously described [<xref ref-type="bibr" rid="CR17">17</xref>]. Thorough environmental disinfection by sodium hypochlorite 1,000&#xA0;ppm was done twice daily. At the time of bathing, the patient&#x2019;s clothes, underwear, and bed linens were replaced and sent for hot laundry daily. Probiotic <italic>Lactobacillus rhamnosus</italic> GG 80&#xA0;mg daily for repopulating the gram positive anaerobic flora was used after the 5-day course of linezolid and daptomycin to consolidate the effect of decolonization and may improve the colonization resistance against re-colonization by VRE. In fact, use of <italic>Lactobacillus rhamnosus</italic> GG or <italic>Lactobacillus rhamnosus</italic> Lcr35 had been attempted to decolonize 49 patients in the literature with variable results (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>). A randomized placebo-controlled study using standard dose of <italic>Lactobacillus</italic> for 3&#xA0;weeks in children showed that rectal swab was rendered negative for VRE at the end of therapy in 63% of patients using semi-quantitative method without broth enrichment, but the difference in VRE carrier state was no longer significant 1&#xA0;week after completion of treatment [<xref ref-type="bibr" rid="CR18">18</xref>], suggesting that the effect of <italic>Lactobacillus</italic> alone may be temporary. Furthermore, using probiotic containing <italic>Lactobacillus species</italic> alone may not be feasible in patient receiving antibiotics [<xref ref-type="bibr" rid="CR19">19</xref>]. In contrast, with the appropriate use of fecal wash-out, antimicrobial agents, and <italic>Lactobacillus rhamnosus GG</italic>, our patients appeared to maintain a persistent VRE negative status, tested by broth enrichment culture of fecal samples, despite the use of broad-spectrum antibiotics after the decolonization.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Summary of gastrointestinal decolonization of vancomycin</bold>-<bold>resistant enterococci by probiotic therapy</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ref</th><th>Country/year of publication/study setting</th><th>Decolonization regimens/study end point(if mentioned)</th><th>Results at study end point</th><th>Microbiology culture methods/presence of broth enrichment or not</th></tr></thead><tbody><tr><td>[<xref ref-type="bibr" rid="CR20">20</xref>]</td><td>Australia/2007/double-blind, randomized, placebo-controlled trial in nephrology patients</td><td>
<italic>Lactobacillus rhamnosus</italic> GG in the form of commercially available yoghurt: 100 g daily of yoghurt containing <italic>Lactobacillus rhamnosus</italic> GG for 4 weeks/follow up for 4 weeks post treatment</td><td>VRE negative in all 11 patients in treatment group at the end of therapy; 8 (73%) remained VRE negative 4&#xA0;weeks post treatment; VRE negative in 1 (8%) of 12 control patient at the end of treatment</td><td>Enterococcosel agar (BD, Sparks, Md, USA) containing 6&#xA0;&#x3BC;g vancomycin/no broth enrichment</td></tr><tr><td>[<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>France/2010/double-blind randomized pilot study in adult</td><td>
<italic>Lactobacillus rhamnosus</italic> Lcr35: 5-week course of Lcr35 (10<sup>9</sup> active cells daily) or a placebo/follow up till the end of therapy</td><td>VRE negative in 3 (50%) of 6 patients in treatment group vs 2 (100%) of 2 patients in control group at the end of therapy</td><td>Not mentioned</td></tr><tr><td>[<xref ref-type="bibr" rid="CR18">18</xref>]</td><td>Poland/2011/randomized, single-blind, placebo-controlled study in children</td><td>
<italic>Lactobacillus rhamnosus</italic> GG 3 billion colony forming unit per day vs placebo for 21&#xA0;days/follow up till the end of therapy</td><td>VRE negative in 20 (63%) of 32 patients in treatment group vs 7 (24%) of 29 in control group (p&#x2009;=&#x2009;0.002)</td><td>Selective medium (D-Coccosel agar, BioMe&#x2019;rieux) and a chromogenic medium (ChromID, BioMe&#x2019;rieux)/no broth enrichment</td></tr></tbody></table><table-wrap-foot><p>Note: VRE, vancomycin-resistant enterococci.</p></table-wrap-foot></table-wrap></p>
      <p>The major limitation in this study is that the experience with our decolonization regimen was restricted to four patients to date. Additionally, there are potential risks and discomfort associated with the use of polyethylene glycol for fecal wash-out. Patients with severe renal impairment may have a risk of fluid retention and electrolyte disturbance. Patients with refractory ascites may not be able to tolerate the volume of polyethylene glycol. Inadequate bowel preparation may subsequently result in failure of VRE decolonization, like case 2 in our series. Further clinical trials should be performed to validate the effectiveness of this regimen and assess the potential development of antimicrobial resistance, as linezolid and daptomycin will be increasingly used in hospitals with rising incidence of infections due to resistant organisms [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Stool concentration of oral linezolid and daptomycin can be done to compare against the measured MICs of the VRE isolates. However, we believe that the findings in this study are significant, where high-risk patient (case 1) with critical underlying co-morbidities has remained VRE negative for over 100&#xA0;days after decolonization, even with subsequent use of broad-spectrum antibiotic therapy. Cost-effective analysis should be conducted in subsequent studies to measure the expenditure in VRE decolonization and medical management of invasive VRE infections. In addition, VRE decolonization on an outpatient basis, such as patient&#x2019;s own residence, may be explored, especially in resource-poor regions where prolonged hospitalization for the purpose of decolonization may not be feasible.</p>
    </sec>
    <sec id="Sec6">
      <title>Conclusion</title>
      <p>Our experience revealed that sustained decolonization of gastrointestinal carriage of VRE was possible by a combination of environmental disinfection, patient isolation, bowel preparation to wash-out the fecal bacterial population using polyethylene glycol, a five-day course of oral absorbable linezolid and non-absorbable daptomycin to suppress any remaining VRE, and subsequent oral <italic>Lactobacillus rhamnosus</italic> GG to maintain the colonization resistance. This strategy should be further studied in settings of low VRE endemicity with limited isolation facilities.</p>
      <sec id="Sec7">
        <title>Consent</title>
        <p>Written informed consent was obtained from the four patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
      <sec id="Sec8">
        <title>Ethics statement</title>
        <p>This study has been approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.</p>
      </sec>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec9">
          <title>Authors&#x2019; original submitted files for images</title>
          <p>Below are the links to the authors&#x2019; original submitted files for images.<media position="anchor" xlink:href="12879_2014_3833_MOESM1_ESM.pdf" id="MOESM1"><caption><p>Authors&#x2019; original file for figure 1</p></caption></media><media position="anchor" xlink:href="12879_2014_3833_MOESM2_ESM.pdf" id="MOESM2"><caption><p>Authors&#x2019; original file for figure 2</p></caption></media><media position="anchor" xlink:href="12879_2014_3833_MOESM3_ESM.pdf" id="MOESM3"><caption><p>Authors&#x2019; original file for figure 3</p></caption></media><media position="anchor" xlink:href="12879_2014_3833_MOESM4_ESM.pdf" id="MOESM4"><caption><p>Authors&#x2019; original file for figure 4</p></caption></media></p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors' contributions</bold>
        </p>
        <p>VCCC and KYY designed, executed and supervised the study. VCCC, JWMT, and SCYW coordinated the infection control and collection of clinical specimens. JHKC and RWSP conducted quantitative culture and molecular characterization of VRE strains. VCCC drafted the manuscript. IFNH, KKWT, JFWC, PLH, CML and KYY critically reviewed the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Funding source</title>
      <p>This work was supported by the commissioned research grant from the Health and Medical Research Fund of the Food and Health Bureau, Hong Kong Special Administrative Region.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willems</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Top</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van Santen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Coque</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Baquero</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Grundmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bonten</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex</article-title>
          <source>Emerg Infect Dis</source>
          <year>2005</year>
          <volume>11</volume>
          <issue>6</issue>
          <fpage>821</fpage>
          <lpage>828</lpage>
          <pub-id pub-id-type="doi">10.3201/1106.041204</pub-id>
          <pub-id pub-id-type="pmid">15963275</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>So</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Hung</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>KY</given-names>
            </name>
          </person-group>
          <article-title>Proactive infection control measures to prevent nosocomial transmission of vancomycin-resistant enterococci in Hong Kong</article-title>
          <source>J Formos Med Assoc</source>
          <year>2014</year>
          <volume>113</volume>
          <issue>10</issue>
          <fpage>734</fpage>
          <lpage>741</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jfma.2014.04.001</pub-id>
          <pub-id pub-id-type="pmid">24796821</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>To</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>KY</given-names>
            </name>
          </person-group>
          <article-title>Successful control of vancomycin-resistant Enterococcus faecium outbreak in a neurosurgical unit at non-endemic region</article-title>
          <source>Emerg Health Threats J</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>e9</fpage>
          <pub-id pub-id-type="pmid">22460290</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>IW</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Extensive contact tracing and screening to control the spread of vancomycin-resistant Enterococcus faecium ST414 in Hong Kong</article-title>
          <source>Chin Med J (Engl)</source>
          <year>2012</year>
          <volume>125</volume>
          <issue>19</issue>
          <fpage>3450</fpage>
          <lpage>3457</lpage>
          <pub-id pub-id-type="pmid">23044305</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russell</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Flood</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zaroda</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Acosta</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Busuttil</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Pegues</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients</article-title>
          <source>Am J Transplant</source>
          <year>2008</year>
          <volume>8</volume>
          <issue>8</issue>
          <fpage>1737</fpage>
          <lpage>1743</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02304.x</pub-id>
          <pub-id pub-id-type="pmid">18557723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Tse</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>To</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>KY</given-names>
            </name>
          </person-group>
          <article-title>Proactive infection control measures to prevent nosocomial transmission of carbapenem-resistant Enterobacteriaceae in a non-endemic area</article-title>
          <source>Chin Med J (Engl)</source>
          <year>2013</year>
          <volume>126</volume>
          <issue>23</issue>
          <fpage>4504</fpage>
          <lpage>4509</lpage>
          <pub-id pub-id-type="pmid">24286415</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Donovan</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Fan-Havard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tecson-Tumang</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Eng</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin</article-title>
          <source>Diagn Microbiol Infect Dis</source>
          <year>1994</year>
          <volume>18</volume>
          <issue>2</issue>
          <fpage>105</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1016/0732-8893(94)90074-4</pub-id>
          <pub-id pub-id-type="pmid">8062527</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chia</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Nakata</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>McKee</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium</article-title>
          <source>Clin Infect Dis</source>
          <year>1995</year>
          <volume>21</volume>
          <issue>6</issue>
          <fpage>1520</fpage>
          <pub-id pub-id-type="doi">10.1093/clinids/21.6.1520</pub-id>
          <pub-id pub-id-type="pmid">8749657</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstein</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Dedier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brunton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Conly</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium</article-title>
          <source>Clin Infect Dis</source>
          <year>1999</year>
          <volume>29</volume>
          <issue>2</issue>
          <fpage>361</fpage>
          <lpage>366</lpage>
          <pub-id pub-id-type="doi">10.1086/520216</pub-id>
          <pub-id pub-id-type="pmid">10476743</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mondy</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mundy</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium</article-title>
          <source>Clin Infect Dis</source>
          <year>2001</year>
          <volume>33</volume>
          <issue>4</issue>
          <fpage>473</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="doi">10.1086/321895</pub-id>
          <pub-id pub-id-type="pmid">11462182</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brossier</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lefrancois</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Paute</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gouot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Golmard</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Chaibi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pautas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Berigaud</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Drieux</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jarlier</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Aubry</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Decolonisation for early control of an outbreak of vancomycin-resistant Enterococcus faecium in a geriatric rehabilitation care facility</article-title>
          <source>J Hosp Infect</source>
          <year>2010</year>
          <volume>76</volume>
          <issue>4</issue>
          <fpage>368</fpage>
          <lpage>369</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhin.2010.06.020</pub-id>
          <pub-id pub-id-type="pmid">20850898</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hachem</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Raad</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci</article-title>
          <source>Infect Control Hosp Epidemiol</source>
          <year>2002</year>
          <volume>23</volume>
          <issue>1</issue>
          <fpage>43</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1086/501968</pub-id>
          <pub-id pub-id-type="pmid">11868893</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montecalvo</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2003</year>
          <volume>51</volume>
          <issue>Suppl 3</issue>
          <fpage>iii31</fpage>
          <lpage>iii35</lpage>
          <pub-id pub-id-type="pmid">12801940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Kauffman</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Standiford</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fort</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Wenzel</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <article-title>Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin</article-title>
          <source>Clin Infect Dis</source>
          <year>2001</year>
          <volume>33</volume>
          <issue>9</issue>
          <fpage>1476</fpage>
          <lpage>1482</lpage>
          <pub-id pub-id-type="doi">10.1086/322687</pub-id>
          <pub-id pub-id-type="pmid">11588692</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montecalvo</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Horowitz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wormser</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Seiter</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Carbonaro</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>1995</year>
          <volume>39</volume>
          <issue>3</issue>
          <fpage>794</fpage>
          <pub-id pub-id-type="doi">10.1128/AAC.39.3.794</pub-id>
          <pub-id pub-id-type="pmid">7793898</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eisenstein</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Oleson</surname>
              <given-names>FB</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Baltz</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD</article-title>
          <source>Clin Infect Dis</source>
          <year>2010</year>
          <volume>50</volume>
          <issue>Suppl 1</issue>
          <fpage>S10</fpage>
          <lpage>S15</lpage>
          <pub-id pub-id-type="doi">10.1086/647938</pub-id>
          <pub-id pub-id-type="pmid">20067387</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcare-associated infections and colonization with multi-resistant organisms: a systematic review</article-title>
          <source>J Hosp Infect</source>
          <year>2012</year>
          <volume>82</volume>
          <issue>2</issue>
          <fpage>71</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhin.2012.07.005</pub-id>
          <pub-id pub-id-type="pmid">22889522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szachta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ignys</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cichy</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children</article-title>
          <source>J Clin Gastroenterol</source>
          <year>2011</year>
          <volume>45</volume>
          <issue>10</issue>
          <fpage>872</fpage>
          <lpage>877</lpage>
          <pub-id pub-id-type="doi">10.1097/MCG.0b013e318227439f</pub-id>
          <pub-id pub-id-type="pmid">21814146</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Regt</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Willems</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Hene</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Siersema</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Verhaar</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hopmans</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Bonten</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Effects of probiotics on acquisition and spread of multiresistant enterococci</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2010</year>
          <volume>54</volume>
          <issue>7</issue>
          <fpage>2801</fpage>
          <lpage>2805</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.01765-09</pub-id>
          <pub-id pub-id-type="pmid">20404120</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manley</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Fraenkel</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mayall</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Power</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial</article-title>
          <source>Med J Aust</source>
          <year>2007</year>
          <volume>186</volume>
          <issue>9</issue>
          <fpage>454</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">17484706</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vidal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forestier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Charbonnel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Henard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rabaud</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lesens</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans</article-title>
          <source>J Clin Microbiol</source>
          <year>2010</year>
          <volume>48</volume>
          <issue>7</issue>
          <fpage>2595</fpage>
          <lpage>2598</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.00473-10</pub-id>
          <pub-id pub-id-type="pmid">20421444</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kainer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Devasia</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Melton</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Broyles</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Schaffner</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Response to emerging infection leading to outbreak of linezolid-resistant enterococci</article-title>
          <source>Emerg Infect Dis</source>
          <year>2007</year>
          <volume>13</volume>
          <issue>7</issue>
          <fpage>1024</fpage>
          <lpage>1030</lpage>
          <pub-id pub-id-type="doi">10.3201/eid1307.070019</pub-id>
          <pub-id pub-id-type="pmid">18214174</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelesidis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Humphries</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Uslan</surname>
              <given-names>DZ</given-names>
            </name>
            <name>
              <surname>Pegues</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians</article-title>
          <source>Clin Infect Dis</source>
          <year>2011</year>
          <volume>52</volume>
          <issue>2</issue>
          <fpage>228</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/ciq113</pub-id>
          <pub-id pub-id-type="pmid">21288849</pub-id>
        </element-citation>
      </ref>
      <ref-list id="BSec1">
        <title>Pre-publication history</title>
        <ref id="CR24">
          <mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/14/514/prepub">http://www.biomedcentral.com/1471-2334/14/514/prepub</ext-link></mixed-citation>
        </ref>
      </ref-list>
    </ref-list>
  </back>
</article>
</pmc-articleset>
